The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Adropin Is a Novel Regulator of Endothelial Function
Open accessAbstract
Background— Adropin is a recently identified protein that has been implicated in the maintenance of energy homeostasis and insulin resistance. Because vascular function and insulin sensitivity are closely related, we hypothesized that adropin may also exert direct effects on the endothelium. Methods and Results— In vitro cell culture models were partnered with an in vivo murine injury model to determine the potential vascular effects of adropin. Adropin was expressed in human umbilical vein and coronary artery endothelial cells (ECs). Adropin-treated endothelial cells exhibited greater proliferation, migration and capillary-like tube formation and less permeability and tumor necrosis factor-α–induced apoptosis. In keeping with a vascular protective effect, adropin stimulated Akt Ser 473 and endothelial nitric oxide (NO) synthase Ser 1177 phosphorylation. The former was abrogated in the presence of the phosphatidylinositol 3-kinase inhibitor LY294002, whereas the latter was attenuated by LY294002 and by mitogen-activated protein kinase kinase 1 inhibition with PD98059. Together, these findings suggest that adropin regulates NO bioavailability and events via the phosphatidylinositol 3-kinase-Akt and extracellular signal regulated kinase 1/2 signaling pathways. Adropin markedly upregulated vascular endothelial growth factor receptor-2 (VEGFR2) transcript and protein levels, and in VEGFR2-silenced endothelial cells, adropin failed to induce phosphorylation of endothelial NO synthase, Akt, and extracellular signal regulated kinase 1/2, supporting VEGFR2 as an upstream target of adropin-mediated endothelial NO synthase activation. Last, adropin improved murine limb perfusion and elevated capillary density following induction of hindlimb ischemia. Conclusions— We report a potential endothelial protective role of adropin that is likely mediated via upregulation of endothelial NO synthase expression through the VEGFR2-phosphatidylinositol 3-kinase-Akt and VEGFR2-extracellular signal regulated kinase 1/2 pathways. Adropin represents a novel target to limit diseases characterized by endothelial dysfunction in addition to its favorable metabolic profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Couffinhal, T., Silver, M., Zheng, L., Kearney, M., Witzenbichler, B., & Isner, J. M. (1998) · Europe PMC (PubMed Central) · Cited by 672
Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction
Verma, S., Li, S.-H., Wang, C.-H., Fedak, P. W. M., Li, R.-K., Weisel, R. D., & Mickle, D. A. G. (2003) · Circulation · doi:10.1161/01.cir.0000084503.91330.49 · Cited by 670
Self-citationAssociation of Hypoadiponectinemia With Impaired Vasoreactivity
Ouchi, N., Ohishi, M., Kihara, S., Funahashi, T., Nakamura, T., Nagaretani, H., Kumada, M., Ohashi, K., Okamoto, Y., Nishizawa, H., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000083488.67550.b8 · Cited by 590
Endothelial Function Testing as a Biomarker of Vascular Disease
Verma, S., Buchanan, M. R., & Anderson, T. J. (2003) · Circulation · doi:10.1161/01.cir.0000089191.72957.ed · Cited by 569
Self-citationKumar, K. G., Trevaskis, J. L., Lam, D. D., Sutton, G. M., Koza, R. A., Chouljenko, V. N., Kousoulas, K. G., Rogers, P. M., Kesterson, R. A., Thearle, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.011 · Cited by 511
Leptin and Cardiovascular Disease: Response to Therapeutic Interventions
Koh, K. K., Park, S. M., & Quon, M. J. (2008) · Circulation · doi:10.1161/circulationaha.107.741645 · Cited by 479
Strömblad, S., Becker, J. C., Yebra, M., Brooks, P. C., & Cheresh, D. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118808 · Cited by 383
Vascular function, insulin resistance and fatty acids
Steinberg, H., & Baron, A. (2002) · Diabetologia · doi:10.1007/s00125-002-0800-2 · Cited by 341
Regulation of Endothelial Cell Survival and Apoptosis During Angiogenesis
Chavakis, E., & Dimmeler, S. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000017728.55907.a9 · Cited by 285
Ouedraogo, R., Gong, Y., Berzins, B., Wu, X., Mahadev, K., Hough, K., Chan, L., Goldstein, B. J., & Scalia, R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29623 · Cited by 264
Gualillo, O., González-Juanatey, J. R., & Lago, F. (2007) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2007.09.005 · Cited by 193
Adiponectin and cardiovascular disease: state of the art?
Szmitko, P. E., Teoh, H., Stewart, D. J., & Verma, S. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01072.2006 · Cited by 168
Self-citationMather, K. J., Lteif, A., Steinberg, H. O., & Baron, A. D. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2060 · Cited by 160
Insulin resistance and vascular function
Baron, A. D. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00209-4 · Cited by 160
Lovren, F., Pan, Y., Shukla, P. C., Quan, A., Teoh, H., Szmitko, P. E., Peterson, M. D., Gupta, M., Al-Omran, M. A., & Verma, S. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90780.2008 · Cited by 115
Self-citationKadoglou, N. P. E., Sailer, N., Moumtzouoglou, A., Kapelouzou, A., Tsanikidis, H., Vitta, I., Karkos, C. D., Karayannacos, P., Gerasimidis, T., & Liapis, C. D. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1237360 · Cited by 93
Teoh, H., Quan, A., Bang, K. W. A., Wang, G., Lovren, F., Vu, V. P., Haitsma, J. J., Szmitko, P. E., Al-Omran, M. A., Wang, C., et al. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90384.2008 · Cited by 92
Self-citationAdiponectin and cardiovascular inflammatory responses
Takemura, Y., Walsh, K. X., & Ouchi, N. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0025-4 · Cited by 63
Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis.
Matarese, G., Mantzoros, C., & Cava, A. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207783018635 · Cited by 62
Masked Hypertension and Atherogenesis: The Impact on Adiponectin and Resistin Plasma Levels
Papadopoulos, D. P., Perrea, D. N., Thomopoulos, C., Sanidas, E. A., Daskalaki, M., Papazachou, U. G., Votteas, V., & Makris, T. K. (2009) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00070.x · Cited by 32
Cited by
Endothelial dysfunction — A major mediator of diabetic vascular disease
Sena, C. M., Pereira, A. M., & Seiça, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.006 · Cited by 797
Paul, S., & Candelario-Jalil, E. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113518 · Cited by 748
Adropin Deficiency Is Associated With Increased Adiposity and Insulin Resistance
Ganesh‐Kumar, K., Zhang, J., Gao, S., Rossi, J., McGuinness, O. P., Halem, H. H., Culler, M. D., Mynatt, R. L., & Butler, A. A. (2012) · Obesity · doi:10.1038/oby.2012.31 · Cited by 262
Three new players in energy regulation: Preptin, adropin and irisin
Aydin, S. (2014) · Peptides · doi:10.1016/j.peptides.2014.03.021 · Cited by 255
Vita, J. A. (2011) · Circulation · doi:10.1161/circulationaha.111.078824 · Cited by 195
Metadata
- Authors
- Lovren, F., Pan, Y., Quan, A., Singh, K. K., Shukla, P. C., Gupta, M., Al-Omran, M., Teoh, H., & Verma, S.
- Venue
- Circulation
- Published
- 2010-09-14
- Volume
- 122
- Issue
- 11_suppl_1
- Pages
- S185-92
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2086087714
- Cited by
- 316
- References
- 20
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.